CLOV three-lens brief
Evidence-based stock research on CLOV. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Outperforming SPY by 16.2pp over 30 days. · RSI at 72 — technically overbought.
- RSI at 72 — technically overbought.
- Outperforming SPY by 16.2pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $2.82 — 16% above current (3 analysts).
- Negative free cash flow last quarterly (-$37.40M).
CLOV closed at $2.43 (+1.25%) as of 2026-04-25. Market cap: $1.27B. Positives: outperforming SPY by 16.2pp over 30 days.; analyst mean target $2.82 — 16% above current (3 analysts).. Concerns: rSI at 72 — technically overbought.; currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $487.71M, net income -$49.32M, free cash flow -$37.40M.
Why three lenses on CLOV, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CLOVacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CLOV" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CLOV brief"></iframe>